biostudies-literatureUnknown3(4)Salter KH<h4>Background</h4>A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. This emphasizes the need to evaluate every patient's probability of responding to each chemotherapeutic agent and limiting the agents used to those most likely to be effective.<h4>Methods and results</h4>Using gene expression data on the NCI-60 and corresponding drug sensitivity, mRNA and microRNA profiles were developed representing sensitivity to individual chemotherapeutic agents. The mRNA signatures were tested in an independent cohort of 133 breast cancer patients treated with the TFAC (paclitaxel, 5-fluorouracil, adriamycin, andPloS onee1908https://www.ebi.ac.uk/biostudies/studies/S-EPMC2270912biostudies-literatureAn integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.PMC2270912Acharya CRSalter KHAnguiano ANevins JRMarcom KPDressman HKRedman RBarry WTMukherjee SGarman KSAnders CKWalters KSPotti AOlson JfalseAn integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.<h4>Background</h4>A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer patients. This emphasizes the need to evaluate every patient's probability of responding to each chemotherapeutic agent and limiting the agents used to those most likely to be effective.<h4>Methods and results</h4>Using gene expression data on the NCI-60 and corresponding drug sensitivity, mRNA and microRNA profiles were developed representing sensitivity to individual chemotherapeutic agents. The mRNA signatures were tested in an independent cohort of 133 breast cancer patients treated with the TFAC (paclitaxel, 5-fluorouracil, adriamycin, and2008-01-01T00:00:00Z2008 Apr2026-05-29T16:00:40.311Z2025-08-31T03:08:36.022ZS-EPMC22709121838268110.1371/journal.pone.0001908